0001209191-16-142357.txt : 20160921 0001209191-16-142357.hdr.sgml : 20160921 20160921212954 ACCESSION NUMBER: 0001209191-16-142357 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160919 FILED AS OF DATE: 20160921 DATE AS OF CHANGE: 20160921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kaye Edward M. MD CENTRAL INDEX KEY: 0001522780 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 161896579 MAIL ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY CITY: BOTHELL STATE: WA ZIP: 98011 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-09-19 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001522780 Kaye Edward M. MD 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 1 1 0 0 President, CEO & CMO Common Stock 2016-09-19 4 M 0 13000 8.28 A 89983 D Common Stock 2016-09-19 4 S 0 13000 50.00 D 76983 D Common Stock 2016-09-19 4 M 0 947 5.40 A 77930 D Common Stock 2016-09-19 4 S 0 947 50.00 D 76983 D Common Stock 2016-09-19 4 M 0 10405 5.40 A 87388 D Common Stock 2016-09-19 4 S 0 10405 50.00 D 76983 D Non-Qualified Stock Options (right to buy) 13.90 2016-09-19 4 M 0 13000 8.28 D 2012-06-20 2012-06-20 Common Stock 13000 80358 D Incentive Stock Options (right to buy) 5.40 2016-09-19 4 M 0 947 5.40 D 2013-04-24 2022-04-24 Common Stock 947 0 D Non-Qualified Stock Options (right to buy) 5.40 2016-09-19 4 M 0 10405 5.40 D 2013-04-24 2022-04-24 Common Stock 10405 0 D This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. /s/David Tyronne Howton, as Attorney-in-Fact for Edward M. Kaye 2016-09-21